ClinicalTrials.gg
CompletedNCT02924402Updated Nov 13, 2024

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

A Phase 1 interventional study of XmAb13676 in B-cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, sponsored by Xencor, Inc.. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-13.

Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
154
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 169 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in France — 33 open to participants now, 58 under way, 21 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · France.

Enrollment
84th of 148
154 · median 173
Started
2016
with 4 others
Phase 1
31 of 169
4 open now
Registered
86th of 169
by date

Among the 169 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in France, this one is the 84th largest by enrollment of the 148 interventional ones that give a count, is one of 5 that started in 2016, is one of 31 in phase 1, and was the 86th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

33 of the 169 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in France are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).

03

Conditions studied

  • B-cell Non-Hodgkins Lymphoma
  • Chronic Lymphocytic Leukemia

Keywords

  • NHL
  • B-cell Prolymphocytic Leukemia
  • Transformed Lymphoma
  • Burkitt's Lymphoma
  • Mantle Cell Lymphoma
  • Hairy Cell Leukemia
  • Splenic Marginal Zone Lymphoma
  • Waldenstrom's Macroglobulinemia
  • Variant Hairy Cell Leukemia
  • Splenic B-cell Lymphoma/Leukemia
  • Lymphoplasmacytic Lymphoma
  • Extranodal Marginal Zone Lymphoma (MALT)
  • MALT Lymphoma
  • Nodal Marginal Zone Lymphoma
  • Follicular Lymphoma
  • In Situ Follicular Neoplasia
  • Duodenal-type Follicular Lymphoma
  • Large B-cell Lymphoma with IRF4 rearrangement
  • Primary Cutaneous Follicle Center Lymphoma
  • Diffuse Large B-cell Lymphoma
  • DLBCL
  • T-cell/Histiocyte-Rich Large B-cell Lymphoma
  • Primary Cutaneous DLBCL, leg type
  • EBV-positive DLBCL, NOS
  • EBV-positive Mucocutaneous Ulcer
  • DLBCL Associated with Chronic Inflammation
  • Lymphomatoid Granulomatosis
  • Primary Mediastinal (Thymic) Large B-cell Lymphoma
  • Intravascular Large B-cell Lymphoma
  • ALK+ Large B-cell Lymphoma
  • Plasmablastic Lymphoma
  • Primary Effusion Lymphoma
  • HHV8+ DLBCL
  • Burkitt-like Lymphoma with 11q Aberration
  • High-grade B-cell Lymphoma
  • B-cell Lymphoma, unclassifiable
  • Post-transplant Lymphoproliferative Disorder
  • PTLD
  • SLL
  • High-grade Lymphoma
  • Richter's Transformation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written
  • Diagnosis of either Non-CLL B cell
  • Ineligible for or have exhausted standard therapeutic options and have disease
  • performance status 0-2
  • Fertile patients must agree to use highly effective during and for 5 months (male patients) and 8 months (female patients) after last dose of XmAb13676
  • Able and willing to complete the entire study

Additional Patient Inclusion Criteria for the DLBCL Cohort (Expansion Phase)

  1. confirmed diagnosis (specified by 2016 World Health Organization) of DLBCL or transformed low-grade lymphoma with
  2. Patient must be refractory or have relapsed after 2 or more standard therapeutic options, at least one of which must have included anti-CD20 antibody therapy.
  3. Not a candidate for or refusing treatment with hematopoietic stem cell transplantation

Additional Patient Inclusion Criteria for the Follicular Lymphoma Cohort (Expansion Phase)

  1. Diagnosis of follicular lymphoma Grades 1-3a
  2. Patient must be ineligible for or have exhausted standard therapeutic options and have had 2 or more prior systemic regimens.

Exclusion criteria

Exclusion Criteria:

  • Cytotoxic chemotherapy, radiotherapy, or immunotherapy including other anti-CD20 antibodies within 4 weeks, or small molecule or agents within 5 elimination half-lives of the first dose of XmAb13676
  • Prior solid organ transplantation
  • Failure to recover from Grade 3 or 4 toxicity from previous treatment
  • Multiple myeloma/plasma cell leukemia or B cell acute lymphoblastic leukemia
  • Known intolerance to CD20 monoclonal antibody therapy
  • History of primary central nervous system lymphoma or neoplastic central nervous system disease
  • count \< 50 x 10\^9/L
  • \< 1.0 x 10\^9/L
  • (AST) and alanine aminotransferase (ALT) at screening > 3x (ULN)
  • > 1.5 mg/dL unless prior diagnosis and documentation of ongoing hemolysis or Gilbert's syndrome has been made)
  • Estimated \< 40 mL/min
  • Active/uncontrolled disease
  • cardiac/cardiovascular disease, or pulmonary compromise
  • Seizure disorder
  • History of stroke with the past 6 mos prior to study entry
  • History or evidence of a clinically unstable/uncontrollable disorder, condition or disease other than primary , that in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures or completion
  • Evidence of any serious bacterial, viral, parasitic or systemic fungal infections within the 30 days prior to study entry
  • Positive test for (HIV) or (HCV) antibodies (unless HCV viral load test by PCR is negative)
  • Positive test for HbsAg, or positive test for (unless serology is positive due to recent intravenous immunoglobulin therapy). HBcAb positivity will be allowed if HBsAb is present or HBV-DNA is negative and patient is receiving Hep B reactivation prophylaxis.
  • Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, and 8 months after the last dose of study drug
  • Positive urine pregnancy test (ie, urine human chorionic gonadotropin) at screening
  • Live viral vaccine within 2 weeks of the first dose of XmAb13676
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Non-CLL B Cell Malignancies (Group NHL) Part A

    XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

    Biological: XmAb13676

  • Experimental
    CLL/SLL (Group CLL) Part A

    XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

    Biological: XmAb13676

  • Experimental
    Non-CLL B Cell Malignancies (Group NHL) Part B

    XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

    Biological: XmAb13676

  • Experimental
    CLL/SLL (Group CLL) Part B

    XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

    Biological: XmAb13676

  • Experimental
    Non-CLL B Cell Malignancies (Group NHL) Part C / Expansion

    XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

    Biological: XmAb13676

  • Experimental
    Non-CLL B Cell Malignancies (Group NHL) Part D / Expansion

    XmAb13676 administered SC up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

    Biological: XmAb13676

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability as determined by the number of participants with treatment-related adverse events as assessed by CTCAE v4.03

    Time frame: Baseline Day 1 through Day 56

  2. Identify maximum tolerated (MTD) and/or recommended dose (RD) and schedule for XmAb13676 dosing

    Time frame: Baseline Day 1 through Day 56

07

Study locations

23 sites
  • Moores UC San Diego Cancer Center
    La Jolla, California 92093, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • The University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • The Ohio State University Wexner Medical Center and James Cancer Hospital
    Columbus, Ohio 43210, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • UVA Health System, Division of Hematology & Oncology
    Charlottesville, Virginia 22908, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Froedtert Hospital and Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
    Bordeaux, 33076, France
  • Hopital Henri Mondor
    Creteil, 94010, France
  • Institut Paoli Calmette Dpt of Oncology/Hematology
    Marseille Cedex 9, 13273, France
  • Chu Montpellier, Hematologie Clinique St. Eloi
    Montpellier Cedex 5, 34295, France
  • CHU de Nantes
    Nantes, 44000, France
  • Centre Antoine Lacassagne
    Nice Cedex, 06189, France
  • CHU Haut-Leveque, Service d'Hematologie Clinique et Therapie Cellulaire
    Pessac, 33604, France
  • Centre Hospitalier Lyon-Sud, Service d'Hematologie
    Pierre-Benite Cedex, 69495, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Institut Universitaire du Cancer Toulouse Oncopole
    Toulouse, 31100, France
  • CLCC Institut Gustave Roussy
    Villejuif, 94805, France
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Royal Marsden Hospital (RMH) - Royal Marsden NHS Foundation Trust
    London, SW3 6JJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Apr 2024, 90 months.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 90 months is above that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2016
First posted
Oct 5, 2016
StartActual
Oct 2016
Primary completionActual
Apr 2024
CompletionActual
Apr 2024
Last update
Nov 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02924402
Lead sponsor
Xencor, Inc.
Collaborators
ICON Clinical Research
Responsible party
Sponsor
First posted
Oct 5, 2016
Start date
Oct 2016
Primary completion
Apr 2024
Completion
Apr 2024
Last update
Nov 13, 2024

Study contacts

Chet Bohac, PharmD, MD, MSc
study director · Executive Medical Director, Clinical Development, Xencor, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plamotamab

Start the discussion